AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27891190 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27891230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 0.02 mg/kg
Number of subjects: 0
Study 27891230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 0.04 mg/kg
Number of subjects: 0
Study 27891230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 0.06 mg/kg
Number of subjects: 0
Study 27891264 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-activated bone substitute composed of collagen-hydroxyapatite scaffold and plasmid DNA encoding vascular endothelial growth factor
Number of subjects: 1
Study 27891264 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-activated bone substitute
Number of subjects: 1
Study 27893465 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 64
Study 27893465 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 64
Study 27893465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharidin-induced skin blisters
Number of subjects: 64
Study 27893465 — intervention group
Group type: EXPERIMENTAL
Intervention: D-resolvin pathway
Number of subjects: 64
Study 27894069 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial (LA) size measurements
Number of subjects: 39
Study 27894069 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative measurements of LA and diastolic function
Number of subjects: 39
Study 27894069 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of asymptomatic patients with increased hemodynamic burden
Number of subjects: 39
Study 27895003 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein supplementation (1.2 g/kg IBW per day)
Number of subjects: 0
Study 27895003 — intervention group
Group type: COMPARATOR
Intervention: Standard protein supplementation (0.8 g/kg IBW per day)
Number of subjects: 0
Study 27895016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV/r) prophylaxis
Number of subjects: 161
Study 27895016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC) prophylaxis
Number of subjects: 161
Study 27895026 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Terminal Pro-Brain Natriuretic Peptide
Number of subjects: 0
Study 27895026 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Natriuretic Peptide
Number of subjects: 0
Study 27895066 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status assessments and longitudinal follow-up examinations
Number of subjects: 600
Study 27895069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using a neuropsychological battery at baseline.
Number of subjects: 309
Study 27895069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment with a focus on memory.
Number of subjects: 309
Study 27895069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment with a focus on executive function.
Number of subjects: 309
Study 27895069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment with a focus on attention.
Number of subjects: 309
Study 27895279 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G (IgG) responses to malaria
Number of subjects: 0
Study 27895279 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27895500 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 249
Study 27895500 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 249
Study 27895549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 0
Study 27896243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ-197)
Number of subjects: 0
Study 27896243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27896545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release 40 mg administered intramuscularly every 28 days
Number of subjects: 44
Study 27896545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release for ≥3 months (n=42)
Number of subjects: 44
Study 27896545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release for ≥15 months (n=10)
Number of subjects: 44
Study 27896545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release
Number of subjects: 44
Study 27896822 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once-daily plus Sofosbuvir 400 mg once-daily for 12 weeks
Number of subjects: 40
Study 27896822 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus Sofosbuvir treatment
Number of subjects: 40
Study 27898284 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-TG storage in muscle tissue
Number of subjects: 23
Study 27898284 — intervention group
Group type: COMPARATOR
Intervention: LPL activity
Number of subjects: 23
Study 27898284 — intervention group
Group type: COMPARATOR
Intervention: LPL activity in abdominal fat
Number of subjects: 23
Study 27898687 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to young children
Number of subjects: 1646
Study 27898687 — intervention group
Group type: EXPERIMENTAL
Intervention: Older ages
Number of subjects: 1646
Study 27898687 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger ages
Number of subjects: 1646
Study 27898728 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with NTHi infection (NTHi+ve)
Number of subjects: 32
Study 27898728 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi+ve COPD patients
Number of subjects: 32
Study 27898728 — intervention group
Group type: COMPARATOR
Intervention: NTHi-negative COPD patients
Number of subjects: 32
Study 27899340 — intervention group
Group type: EXPERIMENTAL
Intervention: CopeSmart mobile phone app
Number of subjects: 208
Study 27899339 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook-delivered health communication intervention targeting mothers
Number of subjects: 2000
Study 27899339 — intervention group
Group type: COMPARATOR
Intervention: Attention-control Facebook private group
Number of subjects: 2000
Study 27899339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 2000
Study 27899488 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27899490 — intervention group
Group type: EXPERIMENTAL
Intervention: GoCARB System for carbohydrate estimation
Number of subjects: 0
Study 27899499 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (n = 188)
Number of subjects: 391
Study 27899499 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients (n = 163)
Number of subjects: 391
Study 27899499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diabetes types
Number of subjects: 391
Study 27899499 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 80 total, 40 each group)
Number of subjects: 391
Study 27899752 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO prevalence in cryptogenic stroke patients (ASCO 0 and 3)
Number of subjects: 3497
Study 27899752 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 3 patients
Number of subjects: 3497
Study 27899752 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 0 patients
Number of subjects: 3497
Study 27899752 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 0- patients
Number of subjects: 3497
Study 27899752 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 0+ patients
Number of subjects: 3497
Study 27899756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific coagulation tests (international normalized ratio, activated partial thromboplastin time, and thrombin time)
Number of subjects: 290
Study 27899756 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific coagulation tests (antifactor Xa tests, hemoclot assay)
Number of subjects: 290
Study 27899756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific coagulation tests (activated partial thromboplastin time and international normalized ratio)
Number of subjects: 290
Study 27899756 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 290
Study 27899756 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC treatment
Number of subjects: 290
Study 27899756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific coagulation tests
Number of subjects: 290
Study 27900127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer surgery
Number of subjects: 70
Study 27900127 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising patients
Number of subjects: 70
Study 27900144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) at rest in low-risk asymptomatic middle-aged trained adults
Number of subjects: 674
Study 27900144 — intervention group
Group type: COMPARATOR
Intervention: Ankle-brachial index (ABI) in sedentary individuals (SED)
Number of subjects: 674
Study 27900169 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise and counselling for 6 months
Number of subjects: 0
Study 27900169 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 0
Study 27900169 — intervention group
Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 0
Study 27900169 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 0
Study 27900175 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive free fall acrobatics (intervention jump) involving reducing parachute deployment airspeed and positioning the body head high.
Number of subjects: 0
Study 27900175 — intervention group
Group type: COMPARATOR
Intervention: Control jump (no acrobatic elements).
Number of subjects: 0
Study 27900177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 20
Study 27900177 — intervention group
Group type: COMPARATOR
Intervention: Baseline control
Number of subjects: 20
Study 27900179 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of n-PINP (procollagen type I N-terminal propeptide)
Number of subjects: 65
Study 27900179 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of n-PIIINP (procollagen type III N-terminal propeptide)
Number of subjects: 65
Study 27900179 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of PINP
Number of subjects: 65
Study 27900179 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of PIIINP
Number of subjects: 65
Study 27900199 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (225 min/week)
Number of subjects: 320
Study 27900199 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal diet maintenance)
Number of subjects: 320
Study 27900346 — intervention group
Group type: EXPERIMENTAL
Intervention: ZFN-mediated CCR5 disruption in HSPC; specific dosage and duration not mentioned.
Number of subjects: 0
Study 27900346 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation with naturally occurring homozygous deletion of CCR5 in donor HSPC; specific dosage and duration not mentioned.
Number of subjects: 0
Study 27900372 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal structural model with inverse-probability weighting
Number of subjects: 0
Study 27900372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat results
Number of subjects: 0
Study 27900579 — intervention group
Group type: EXPERIMENTAL
Intervention: AhR stimulation in MCF-7 cell line
Number of subjects: 29
Study 27900579 — intervention group
Group type: EXPERIMENTAL
Intervention: AhR stimulation
Number of subjects: 29
Study 27900579 — intervention group
Group type: EXPERIMENTAL
Intervention: AhR agonist treatment
Number of subjects: 29
Study 27900579 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of AhR and aromatase status
Number of subjects: 29
Study 27900953 — intervention group
Group type: EXPERIMENTAL
Intervention: iBCI with velocity decoder and exponential smoothing dynamics
Number of subjects: 3
Study 27900953 — intervention group
Group type: EXPERIMENTAL
Intervention: iBCI with varied gain (speed scaling) and temporal smoothing parameters
Number of subjects: 3
Study 27900953 — intervention group
Group type: EXPERIMENTAL
Intervention: Control policy model
Number of subjects: 3
Study 27902470 — intervention group
Group type: EXPERIMENTAL
Intervention: QLNC120
Number of subjects: 24
Study 27902648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis cases
Number of subjects: 1200000
Study 27902652 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 200
Study 27903260 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who developed resting hypoxemia
Number of subjects: 678
Study 27903260 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment at Denver
Number of subjects: 678
Study 27903260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline oxygen saturation
Number of subjects: 678
Study 27903260 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported heart failure
Number of subjects: 678
Study 27903260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery (PA) enlargement on computed tomography
Number of subjects: 678
Study 27903260 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior severe COPD exacerbation
Number of subjects: 678
Study 27903260 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who developed hypoxemia
Number of subjects: 678
Study 27903267 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-derived low skeletal muscle quality (assessed by skeletal muscle density)
Number of subjects: 491
Study 27903416 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV (live attenuated Japanese encephalitis vaccine) administered as primary vaccination (Group 1)
Number of subjects: 10000
Study 27903416 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV (live attenuated Japanese encephalitis vaccine) administered as booster vaccination (Group 2)
Number of subjects: 10000
Study 27903614 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient sleep duration (measured by wrist actigraphy)
Number of subjects: 212
Study 27903614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency (measured by wrist actigraphy)
Number of subjects: 212
Study 27903616 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-TnI cutoff of 3 ng/L with low risk ECG
Number of subjects: 4606
Study 27903616 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up mortality in ruled out population
Number of subjects: 4606
Study 27903810 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 20
Study 27904503 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived stem cells (BMSCs)
Number of subjects: 0
Study 27904903 — intervention group
Group type: EXPERIMENTAL
Intervention: WILL-BLEED Risk Score
Number of subjects: 3744
Study 27904903 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 3744
Study 27904903 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 3744
Study 27904903 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <45 ml/min/1.73 m²
Number of subjects: 3744
Study 27904904 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP for prophylaxis (50 IU/kg every fourth day)
Number of subjects: 175
Study 27904904 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP for on-demand treatment (20-75 IU/kg)
Number of subjects: 175
Study 27904904 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP overall
Number of subjects: 175
Study 27906044 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneously dense breasts (50-75% density)
Number of subjects: 242
Study 27906044 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely dense breasts (>75% density)
Number of subjects: 242
Study 27906044 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive margins after surgery
Number of subjects: 242
Study 27906044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense breasts (>50% density) with positive margin, no adjuvant radiotherapy, and no adjuvant chemotherapy
Number of subjects: 242
Study 27906840 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 1868
Study 27908594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (600 mg twice per day for continuous 28 day cycles)
Number of subjects: 206
Study 27908600 — intervention group
Group type: EXPERIMENTAL
Intervention: SERT = 0 (no risk factors)
Number of subjects: 1178
Study 27908600 — intervention group
Group type: EXPERIMENTAL
Intervention: SERT scores 1-4 (presence of risk factors)
Number of subjects: 1178
Study 27908600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion size ≥40 mm
Number of subjects: 1178
Study 27908600 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding during the procedure
Number of subjects: 1178
Study 27908600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade dysplasia
Number of subjects: 1178
Study 27908843 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedically-delegated medication by paramedics (study group)
Number of subjects: 150
Study 27908843 — intervention group
Group type: COMPARATOR
Intervention: Regular EMS missions (control group)
Number of subjects: 150
Study 27909037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberknife with 1 cycle of S-1 simultaneously followed by 2 or 3 cycles of S-1 sequentially
Number of subjects: 190
Study 27909039 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI-HC assessment
Number of subjects: 437000
Study 27909039 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional hazards regression
Number of subjects: 437000
Study 27909081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 0
Study 27911128 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with oxaliplatin and S-1 (DOS2w)
Number of subjects: 34
Study 27911128 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with oxaliplatin and S-1 (DOS3w)
Number of subjects: 34
Study 27911591 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analog treatment
Number of subjects: 1
Study 27911591 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1
Study 27912069 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (Fluarix™ Tetra)
Number of subjects: 120
Study 27912740 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home respite care program by Baluchon Alzheimer
Number of subjects: 372
Study 27912740 — intervention group
Group type: COMPARATOR
Intervention: Standard dementia care (control group)
Number of subjects: 372
Study 27912744 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Specific Quality of Life Scale (SSQOLS)
Number of subjects: 350
Study 27912744 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe functional disability
Number of subjects: 350
Study 27912744 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 350
Study 27912744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admissions
Number of subjects: 350
Study 27912744 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe neurologic pain
Number of subjects: 350
Study 27912744 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' qualitative themes
Number of subjects: 350
Study 27912784 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day) added to metformin (1500-3000 mg/day)
Number of subjects: 121
Study 27912924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 1604
Study 27912924 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 1604
Study 27913777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis
Number of subjects: 150
Study 27913881 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oral leucovorin (S-1/LV)
Number of subjects: 39
Study 27914133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5 mg once daily for 24 weeks
Number of subjects: 50
Study 27914133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone
Number of subjects: 50
Study 27914187 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50
Study 27914187 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrient supply
Number of subjects: 50
Study 27914292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-affinity and low-trapping NMDA receptor antagonists
Number of subjects: 7
Study 27914468 — intervention group
Group type: COMPARATOR
Intervention: Control group from the Take a Stand! Intervention
Number of subjects: 135
Study 27914470 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP level
Number of subjects: 302
Study 27914470 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CRP
Number of subjects: 302
Study 27914470 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom classes
Number of subjects: 302
Study 27914470 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic biomarkers of inflammation
Number of subjects: 302
Study 27914502 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial coronary computed tomographic angiography (CCTA)
Number of subjects: 2000
Study 27914502 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up beyond serial CCTA performance
Number of subjects: 2000
Study 27914861 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE-IPV intervention
Number of subjects: 98
Study 27914971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2-4 (Group A)
Number of subjects: 37
Study 27914971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Group B)
Number of subjects: 37
Study 27914971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Cycle 2 for responders)
Number of subjects: 37
Study 27914971 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 37